Replimune Announces Financial Results for Fiscal Q2 2026 and Shares Corporate Developments

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Nov 06 2025

0mins

Source: Globenewswire

Financial Results: Replimune Group reported a net loss of $83.1 million for the fiscal second quarter ended September 30, 2025, with cash reserves decreasing to $323.6 million, expected to fund operations into late 2026.
FDA Update: The FDA accepted the resubmission of Replimune's Biologics License Application (BLA) for RP1, targeting advanced melanoma, with a decision expected by April 10, 2026.
Clinical Trials: Ongoing trials for RP1 and RP2 are assessing their effectiveness in various cancers, including advanced melanoma and metastatic uveal melanoma, with promising early results reported at recent conferences.
Upcoming Events: Replimune will present new clinical data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, highlighting the potential of RP1 in overcoming resistance to immune checkpoint blockade.

Discover Tomorrow's Bullish Stocks Today

Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.